NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT04194944 2025-10-21LIBRETTO-431Eli Lilly and CompanyPhase 3 Active not recruiting261 enrolled 24 charts
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT04268550 2025-07-11Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2 Active not recruiting124 enrolled
NCT04280081 2025-04-20LIBRETTO-321Eli Lilly and CompanyPhase 2 Active not recruiting77 enrolled 13 charts